GPR33
GPR33: The Receptor Linked to Obesity and Metabolic Syndrome
Introduction
GPR33, a G protein-coupled receptor (GPCR), has emerged as a key player in energy homeostasis and metabolic regulation. Its role in obesity and associated metabolic disorders has drawn significant attention, making it a promising target for therapeutic interventions.
Description
GPR33 is a receptor primarily expressed on the surface of adipocytes (fat cells) and immune cells. It belongs to the rhodopsin-like GPCR family, characterized by its seven transmembrane domains. GPR33 binds to several ligands, including short-chain fatty acids (SCFAs), such as propionate and butyrate, and medium-chain fatty acids (MCFAs), such as octanoic acid.
Associated Diseases
GPR33 dysfunction has been implicated in the pathogenesis of various metabolic disorders, including:
- Obesity: GPR33 deficiency or inhibition leads to increased food intake, reduced energy expenditure, and weight gain.
- Type 2 Diabetes: Impaired GPR33 signaling disrupts glucose metabolism and contributes to insulin resistance.
- Non-alcoholic Fatty Liver Disease (NAFLD): GPR33 activation reduces hepatic lipogenesis and inflammation, mitigating NAFLD progression.
Did you Know ?
Studies have shown that individuals with obesity have significantly lower GPR33 expression compared to lean individuals, suggesting a potential link between GPR33 deficiency and susceptibility to weight gain.
